Senores Pharmaceuticals Ltd (SENORES) Q2FY27 Management Mirror - Sep-2026 Qtr
H1 FY27 Revenue Grows 30% YoY, Tracking the 30%-40% FY27 Growth Guidance Reaffirmed in Jun'26 Qtr
In Sep'26 Qtr concall, management reported that H1 FY27 consolidated revenue grew 30% YoY to INR 372.5 crore and profit after tax grew 31% YoY to INR 67 crore. This performance tracks against the full-year FY27 guidance of 30% to 40% revenue growth and 50% to 60% PAT growth, which was initially introduced in Mar'26 Qtr and reaffirmed in Jun'26 Qtr. Management reaffirmed this FY27 guidance in Sep'26 Qtr, citing stronger H2 seasonality, operating leverage, subsidiary operationalization, and launch visibility, while additionally targeting an annual growth rate of 25% to 30% over the next 2 to 3 years.
5 more themes on the ELITE plan.